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Objectives: Elevated serum phosphate (hyperphosphataemia) usually accom-
panies end-stage renal disease and results from the inability of damaged kidneys 
to effectively regulate phosphate levels. Failure to maintain adequate phosphate 
balance has important clinical consequences, with an increased morbidity and 
risk of mortality. When dietary phosphate restriction is inadequate for control, 
administration of phosphate binders may be required. A number of phosphate 
binders are currently available; however, these often require high doses to control 
serum phosphate levels and this may result in lowered patient compliance. The 
objectives of this research were to assess the pill burden associated with phos-
phate binders and highlight any links between pill burden, patient adherence and 
outcomes in terms of serum phosphate levels. MethOds: A literature review 
was performed using the PubMed database using the search term “phosphate 
binders AND adherence”. Twenty six articles were identified in total, with ten 
relevant articles. Results: Six of the ten relevant articles (60%) found that low 
patient adherence or high pill burden were associated with higher mean serum 
phosphate level, whereas only one article (10%) concluded that no link existed. 
Seven articles reported dose increases with phosphate binder treatment or an 
increased number of pills per patient per day over the treatment course, with two 
reporting that the actual dose of phosphate binders in clinical practice was higher 
than those recommended in clinical guidelines. A high pill burden was found to 
lead to low adherence by three of the articles identified (30%), whereas only one 
of the papers identified did not support this hypothesis (10%). cOnclusiOns: 
This research indicates that there is a high pill burden associated with phosphate 
binders, as well as a requirement in clinical practice for high dosages. There is 
a suggestion that these factors are linked to low patient adherence and poorer 
control of serum phosphate levels.
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Objectives: Health economic evaluations of therapeutic interventions in patients 
with CKD and SHPT requiring dialysis (CKD-SHPT) should incorporate the impact of 
major clinical events related to their disease. However, little is known about the disu-
tility (i.e, utility decrease) associated with cardiovascular (CV) and fracture events in 
the context of CKD-SHPT. The purpose of this study was to estimate, via preference-
based valuation completed by general population respondents, the added disutil-
ity of these events beyond the impact of CKD-SHPT. MethOds: One-year health 
states were developed describing CKD-SHPT and related CV/fracture acute events/
procedures. Events with long-term effects (post one year) were also captured in 
chronic health states. General population participants in Canada completed time 
trade-off (TTO) interviews to assess health state utilities. Respondents initially rated 
the CKD-SHPT health state. Then, events and procedures were added to this health 
state: myocardial infarction (MI); unstable angina (UA); heart failure exacerbation; 
peripheral vascular disease (PVD) ± amputation; stable angina (SA); stroke; hip/arm 
fractures; parathyroidectomy; kidney transplant. Each participant was randomly-
assigned 11 of 16 health states to rate. Results: A total of 199 participants (54.8% 
female; mean age = 46.3 years) completed interviews. Each health state had ≥ 130 
valuations. CKD-SHPT had a mean utility of 0.60 (SD= 0.34). For acute events, mean 
utility decrements additional to CKD-SHPT were: MI, -0.06; UA, -0.05; PVD with 
amputation, -0.33; PVD without amputation, -0.11; heart failure, -0.14; stroke -0.30; 
hip fracture, -0.14; arm fracture, -0.04; parathyroidectomy, +0.02; kidney transplant, 
+0.06. Disutilities for chronic effects were: SA, -0.09; stroke -0.27; PVD with ampu-
tation -0.30; PVD without amputation, -0.12; heart failure, -0.14. cOnclusiOns: 
Valuation of health states representing CKD-SHPT plus major clinical events was 
feasible using TTO with a one-year time horizon. These data will assist investiga-
tors in applying appropriate disutilities to clinical events in economic evaluations 
of treatments for patients with CKD-SHPT requiring dialysis.
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Objectives: To determine the impact of sacral neuromodulation (SNM) on EQ-5D 
index scores and OAB management costs using an Economic Impact Questionnaire 
(EIQ) in patients who failed at least one anticholinergic medication enrolled in the 
InSite study, an ongoing, prospective, multicenter trial of SNM. MethOds: EQ-5D 
and EIQ were administered at baseline, 3-, 6- and 12-months post-implant. OAB-
related expenses included durable and disposable medical supplies and health 
service utilization (emergency room, hospitalizations and outpatient). A total of 340 
Objectives: Mirabegron is a first-in-class beta-3 adrenoceptor agonist for the 
treatment of overactive bladder (OAB) that demonstrated superior efficacy com-
pared to placebo by reducing OAB symptoms and improving HRQoL. We sought 
to assess the cost-effectiveness of mirabegron 50 mg in comparison with current 
antimuscarinics for the treatment of patients with OAB in the UK. MethOds: 
A Markov model was developed to simulate the therapeutic management, the 
changes in symptoms (micturitions and incontinence), and complications in 
hypothetical cohorts of OAB patients. The model was used to predict costs and 
QALYs over 5 years in cohorts initially treated with antimuscarinics or mirabe-
gron 50mg. Effectiveness and safety data were based on the results from a mixed 
treatment comparison (MTC). A calibration approach was used to derive transition 
probabilities from mean changes in frequency of micturitions and incontinence 
episodes. Other input data were obtained from several sources, including scien-
tific literature and expert opinions. Costs were evaluated from the UK National 
Health Service (NHS) perspective and included costs of drug acquisition, GP visits, 
specialist visit, incontinence pad use and botox injections. Utilities were obtained 
from equations predicting EQ-5D index scores according to symptom severity, 
estimated from a clinical trial of Mirabegron. Results: The Mirabegron strategy 
was slightly more expensive and associated with a greater number of QALYs, as a 
result of improved persistence, related to a lower risk of adverse event compared 
to each antimuscarinic. Mirabegron 50mg was found to be cost-effective com-
pared to each antimuscarinic, with an ICER of £340 vs. solifenacin 10mg, £3,607 
versus fesoterodine 4mg, £3,715 vs. tolterodine ER 4mg, £3,878 vs. oxybutynin ER 
10mg, £8,881 versus trospium chloride MR 60 mg, £12,493 versus solifenacin 5mg, 
and £14,234 oxybutynin IR 10mg. cOnclusiOns: Treatment with mirabegron 
appears to be a cost-effective strategy compared with antimuscarinics from a 
UK NHS perspective.
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Objectives: Intravenous (IV) irons are second line treatments for iron deficien-
cies in severe chronic kidney disease (CKD) patients with iron deficiency anaemia. 
Aim of this study was to compare ferumoxytol, a new agent, against IV ferric 
carboxymaltose (FC) and IV iron sucrose (IS), from a Belgian health care payer (BP) 
and hospital perspective (HP). MethOds: The CKD patients were categorized in 
haemodialysis (HD), peritoneal dialysis (PD), non-dialysis (post-renal transplant 
and non-dialysis) and all patients combined. The available IV irons have a simi-
lar efficacy. Adverse events were not included due to missing comparative data 
and low rates. However, the administration time and number of administrations 
differ among treatments. So a cost-minimization analysis was conducted (time 
horizon: 1 year). The average annual need of IV Iron is 3,500 mg in HD, 2,500 mg in 
PD and 1,500 mg in non-dialysis patients. The hospital perspective was modelled 
by deducting the nurse time cost from the hospital fee per administration (HP). 
For the health care payer the administration cost (hospital fee) and the drug costs 
are included (BP). Other costs were excluded because they did not affect the incre-
mental cost of treatment. Results: The total cost (euro 2012) for all patients was 
€ 676.57, € 819.82 and € 617.34 for ferumoxytol, FC and IS, respectively (BP). In the 
renal transplant and non-dialysis subgroups, ferumoxytol is less costly than FC 
and IS (BP). In the HD subgroup (86.77% of all eligible patients), IS is the least costly 
option (BP). The hospital cost in all patients is higher with IS due to more nurse 
time (€ 101.31, € 7.58 and € 144.19 for ferumoxytol, FC and IS) (HP). cOnclusiOns: 
Hospitals benefit from lower administration costs with ferumoxytol and FC (HP). 
From a Belgian payer perspective, ferumoxytol is less costly than FC and more 
costly than IS.
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Objectives: Anaemia is a frequent complication among patients with Chronic 
Kidney Disease (CKD) and is associated with poor outcomes. European data on the 
patterns of treatment of anaemia in non-dialysed (ND) CKD patients are scarce. 
The aim of this study was to describe the anaemia-associated Health Resource 
Utilization (HRU) in an Italian cohort of ND-CKD patients. MethOds: The admin-
istrative data and clinical laboratory files of 5 Italian Local Health Units from 2006 
to 2011 were used to identify ND patients with CKD (stage3b, 4, 5) and anemia. 
Anaemia-related HRU and associated costs were investigated. Results: A total 
of 1175 patients were included; 790 in CKD stage 3b; 331 in stage 4; 54 in stage 5. 
Anaemia-related medications were prescribed to 31.9% of patients and the per-
centage increased along the CKD stages from 28.9% for stage 3b to 42.6% for stage 
5. Among the drug-treated patients Erythropoiesis-stimulating agents were pre-
scribed to 82.6% of CKD stage 5 patients whereas CKD stage 3b patients received 
mostly oral iron (59.6%). Patients receiving any anaemia-related medications 
had lower per patient-per year cost for almost all studied resources compared to 
patients not receiving any medications. For anaemia-related outpatient services 
[drug-treated and not drug-treated]: stage 3b costs per patient year were € 62.12 
and € 62.32 respectively; stage 4 costs were € 52.23 and € 72.76; stage 5 costs were 
€ 55.83 and € 83.08. For general visits: stage 3b costs were € 168.51 and € 170.28; stage 
4 costs were € 124.17 and € 173.79; stage 5 costs were € 134.49 and € 343.63. For CV 
hospitalizations: stage 3b costs were € 1378.63 and € 1828.60; stage 4 costs were 
€ 1185.17 and € 2155.82; stage 5 costs were € 521.61 and € 514.63. cOnclusiOns: 
Among ND CKD patients drug treatment may help control anaemia-related outpa-
tient services and contain CV hospitalization costs and represents an opportunity 
for health care improvement.
